Showing results (851-860 of 5,688) with videos related to
Sort By:
Pageof 569
The Oncologist|August 6, 2017
Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung CancerThomas E StinchcombeThe Oncologist|August 12, 2017
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid TumorsStephen Leong, Rebecca A Moss, Daniel W Bowles, et al.The Oncologist|July 26, 2017
Soft Tissue Sarcomas of the Extremities: Surgical Margins Can Be Close as Long as the Resected Tumor Has No Ink on ItKamran Harati, Ole Goertz, Andreas Pieper, et al.The Oncologist|August 25, 2017
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and BeyondLee Pai-Scherf, Gideon M Blumenthal, Hongshan Li, et al.The Oncologist|July 13, 2016
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal JunctionManish A Shah, Jae-Yong Cho, Iain B Tan, et al.The Oncologist|August 3, 2017
Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective StudyAhmed F Elsayem, Eduardo Bruera, Alan Valentine, et al.The Oncologist|May 27, 2016
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing ToxicityDaniel L Hertz, Allison Deal, Joseph G Ibrahim, et al.The Oncologist|May 27, 2016
The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine TumorsRobert A Ramirez, David T Beyer, Aman Chauhan, et al.The Oncologist|June 5, 2016
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine TumorsNing Jin, Sam J Lubner, Daniel L Mulkerin, et al.The Oncologist|June 12, 2016
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First MetastasisDeborah Kuk, Alexander N Shoushtari, Christopher A Barker, et al.Pageof 569